title: [Tardive dyskinesia: pergolid, a possible therapeutic option].
abstract: OBJECTIVE
  There's still no effective treatment established for Tardive Dyskinesia. Aim of the study was to analyse the effect of pergolide, a D1 and D2 receptor agonist with prevalence for presynaptic auto receptors, in oro-facial tardive dyskinesia by means of a double-blind, placebo controlled cross-over study. Low-dose pergolide should activate presynaptic auto receptors, decrease dopamintransmission and reduce tardive dyskinesia.
  
  
  METHODS
  Assessment of dyskinesia was performed with the computer-assisted technique Digital-Imaging-Processing in addition to the clinical scale AIMS (Abnormal-Involuntary-Movement-Scale). 10 patients with oro-facial dyskinesia were examined for alteration to dyskinesia, psychopathology, vital functions and laborchemical parameter.
  
  
  RESULTS
  Dyskinesia decreased 25 % for relax and 17 % for task conditions under pergolide treatment. Low-dose pergolide showed no side effects or worsening of the psychopathological state. Results of the Digital-Imaging-Processing correlated significantly with the results of clinical AIMS scale, but the computer-assisted technique gives more detailed information about degree and type of the movement disorder.
  
  
  CONCLUSIONS
  Results suggest a therapeutic effect of pergolide in tardive dyskinesia, this has to be verified with a larger study population and longer observation. Assessment of dyskinesia is rater independent and more significant with the computer-assisted technique.
authors.affiliation: Zentralinstitut für Seelische Gesundheit, Mannheim, Germany. diehl@zi-mannheim.de
authors.forename: Alexander
authors.initials: A
authors.lastname: Diehl
authors.forename: Dieter F
authors.initials: DF
authors.lastname: Braus
authors.forename: Christian
authors.initials: C
authors.lastname: Büchel
authors.forename: Bertram
authors.initials: B
authors.lastname: Krumm
authors.forename: Rossella
authors.initials: R
authors.lastname: Medori
authors.forename: Wagner F
authors.initials: WF
authors.lastname: Gattaz
mesh_terms: D000328:Adult; D000368:Aged; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D018592:Cross-Over Studies; D018491:Dopamine Agonists / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D004409:Dyskinesia, Drug-Induced / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D006801:Humans; D007091:Image Processing, Computer-Assisted; D008297:Male; D008875:Middle Aged; D009460:Neurologic Examination / Q000187:drug effects; D018696:Neuroprotective Agents / Q000009:adverse effects / Q000627:therapeutic use*; D010479:Pergolide / Q000009:adverse effects / Q000627:therapeutic use*; D010865:Pilot Projects; D012559:Schizophrenia / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D014150:Antipsychotic Agents; D018491:Dopamine Agonists; D018696:Neuroprotective Agents; D010479:Pergolide
vernacular_title: Tardive Dyskinesien: Pergolid als mögliche therapeutische Option.